Education
About Us
Working with TipRanks
Follow Us
SELLAS Life Sciences Group (SLS)
NASDAQ:SLS
RESEARCH TOOLSreports
SLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.77 - $1.84
Previous CloseN/A
Volume1.43M
Average Volume (3M)4.10M
Market Cap
$92.73M
Enterprise Value$64.76M
Total Cash (Recent Filing)$5.34M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Mar 20, 2025EPS Estimate
-0.11Last Dividend Ex-Date
Apr 27, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding78,581,980
10 Day Avg. Volume1,259,008
30 Day Avg. Volume4,103,149
Standard Deviation0.32
R-Squared0.16
Alpha0.00785
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.33
Forecast
1Y Price Target
$4.00Price Target Upside238.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsSellas announced positive data from a P2a trial for selective CDK9 inhibitor SLS009 (tambiciclib) + approved BTK inhibitor Brukinsa (zanubrutinib) in relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).
Safety And EfficacySellas has also demonstrated continued positive safety and efficacy signals for the triple combination of SLS009 + venetoclax + azacitidine (ven/aza) in relapsed/refractory acute myeloid leukemia (r/r AML).
Bears Say
Stock PerformanceDespite positive trial data, SLS shares were down, possibly due to a slight run-up ahead of the data and some profit-taking, as well as continued pressure in the biotech sector.
---
Ownership Overview
2.01% Insiders
3.57% Mutual Funds
2.67% Other Institutional Investors
88.77% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SLS FAQ
What was SELLAS Life Sciences Group’s price range in the past 12 months?
SELLAS Life Sciences Group lowest stock price was $0.77 and its highest was $1.84 in the past 12 months.
What is SELLAS Life Sciences Group’s market cap?
SELLAS Life Sciences Group’s market cap is $92.73M.
When is SELLAS Life Sciences Group’s upcoming earnings report date?
SELLAS Life Sciences Group’s upcoming earnings report date is Mar 20, 2025 which is in 17 days.
How were SELLAS Life Sciences Group’s earnings last quarter?
SELLAS Life Sciences Group released its earnings results on Nov 13, 2024. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.127 by $0.027.
Is SELLAS Life Sciences Group overvalued?
According to Wall Street analysts SELLAS Life Sciences Group’s price is currently Undervalued.
Does SELLAS Life Sciences Group pay dividends?
SELLAS Life Sciences Group pays a Notavailable dividend of $7025.8 which represents an annual dividend yield of N/A. See more information on SELLAS Life Sciences Group dividends here
What is SELLAS Life Sciences Group’s EPS estimate?
SELLAS Life Sciences Group’s EPS estimate is -0.11.
How many shares outstanding does SELLAS Life Sciences Group have?
SELLAS Life Sciences Group has 78,581,980 shares outstanding.
What happened to SELLAS Life Sciences Group’s price movement after its last earnings report?
SELLAS Life Sciences Group reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.127. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of SELLAS Life Sciences Group?
Among the largest hedge funds holding SELLAS Life Sciences Group’s share is Highbridge Capital Management LLC. It holds SELLAS Life Sciences Group’s shares valued at 0.
---
SELLAS Life Sciences Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (238.98% Upside)
$4.00 (238.98% Upside)
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.83%
12-Months-Change
Fundamentals
Return on Equity
-535.10%
Trailing 12-Months
Asset Growth
227.79%
Trailing 12-Months
Company Description
SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutics for cancer indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. Its products include galinpepimut-S and nelipepimut-S. The company was founded on April 3, 2006 and is headquartered in New York, NY.
---
SLS Stock 12 Month Forecast
Average Price Target
$4.00
▲(238.98% Upside)
Technical Analysis
Best Analysts Covering SLS
1 Year
1 Year Success Rate
8/19 ratings generated profit
1 Year Average Return
-2.51%
reiterated a buy rating 11 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of -2.51% per trade.
---